Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
Daniel T. Scavilla, President and CEO of Globus Medical Inc. (NYSE:GMED), executed significant stock transactions as reported in a recent SEC filing. On November 21, Scavilla sold 130,000 shares of Class A Common Stock at a price of $85 per share, amounting to a total value of $11.05 million. This sale was conducted under a pre-established Rule 10b5-1 trading plan dated June 7, 2024.
In addition to the sale, Scavilla exercised stock options to acquire 130,000 shares of Class A Common Stock at prices ranging from $43.58 to $43.77, totaling approximately $5.67 million. These options were fully vested, having been granted in January 2018 and January 2019. Following these transactions, Scavilla no longer holds any shares directly.
In other recent news, Globus Medical (TASE:PMCN) reported a significant increase in Q3 sales to $626 million, a 63% growth year-over-year. The company also announced a record Non-GAAP EPS of $0.83, a 45% increase, and a record free cash flow of $162 million. These results were largely driven by robust U.S. spine sales, international expansion, and the ongoing integration of the NuVasive (NASDAQ:NUVA) merger.
The company also launched four new products in Q3, bringing the total to 13 for the year. Enabling Technologies revenue rose 39% to $38 million, with robotic procedures growing by 34%. The company revised its 2024 net sales guidance to $2.49 billion to $2.5 billion, and adjusted its non-GAAP EPS guidance to $2.90 to $3 per share.
Looking forward, Globus Medical is focusing on integration and cost synergies, expecting $170 million in savings over three years. The company anticipates stronger growth through increased cross-selling and operational improvements in 2025, and plans to leverage synergy with robotics, particularly in orthopedics. Despite a decrease in gross profit margin to 53% due to the NuVasive merger, and a conservative Q4 growth outlook, the company's management remains confident in its strategic direction and the future growth of its orthopedic products.
InvestingPro Insights
The recent stock transactions by Globus Medical's CEO Daniel T. Scavilla align with several key insights from InvestingPro. Despite the CEO's significant sale, the company's stock has shown robust performance, with InvestingPro data indicating a strong 82.9% return over the past year and a 58.98% year-to-date price total return. This performance is reflected in the stock trading near its 52-week high, with the current price at 99.33% of that peak.
InvestingPro Tips highlight that management has been aggressively buying back shares, which could be seen as a vote of confidence in the company's future prospects. This is particularly noteworthy given Scavilla's recent sale, suggesting a balanced approach to capital management.
The company's financial health appears solid, with InvestingPro data showing a market capitalization of $11.53 billion and revenue of $2.48 billion over the last twelve months as of Q3 2024. The revenue growth is impressive at 102.1% for the same period, indicating strong business momentum.
However, investors should note that Globus Medical is trading at a high earnings multiple, with a P/E ratio of 126.03. This valuation metric suggests that the market has high growth expectations for the company, which aligns with the InvestingPro Tip that net income is expected to grow this year.
For readers interested in a more comprehensive analysis, InvestingPro offers 17 additional tips for Globus Medical, providing a deeper understanding of the company's financial position and market sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.